Methods of administering elagolix

Méthodes d'administration d'élagolix

Abstract

The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.
La présente invention concerne l'utilisation d'antagonistes du récepteur de GnRH utilisés dans le traitement de l'endométriose ou de fibromes utérins. En particulier, la présente invention concerne une méthode pour traiter l'endométriose ou des fibromes utérins, ladite méthode consistant à administrer de l'élagolix, et pouvant également consister à co-administrer la rifampicine ou le kétoconazole.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (1)

    Publication numberPublication dateAssigneeTitle
    WO-2014143669-A1September 18, 2014AbbVie Inc .Compositions for use in treating heavy menstrual bleeding and uterine fibroids

NO-Patent Citations (8)

    Title
    A KALLIOKOSKI ET AL: "Impact of OATP transporters on pharmacokinetics", BRITISH JOURNAL OF PHARMACOLOGY, vol. 158, no. 3, 28 September 2009 (2009-09-28), pages 693 - 705, XP055324152, ISSN: 0007-1188, DOI: 10.1111/j.1476-5381.2009.00430.x
    CHEN CHEN ET AL: "Discovery of Sodium R-(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2- fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H- pyrimidin-1-yl]-1-phenylethylamino}butyrate (Elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 51, no. 23, 1 January 2008 (2008-01-01), pages 7478 - 7485, XP002538508, ISSN: 0022-2623, DOI: 10.1021/JM8006454
    DIAMOND MICHAEL P ET AL: "Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study", REPRODUCTIVE SCIENCES, SAGE PUBLICATIONS, INC, US, vol. 21, no. 3, 1 March 2014 (2014-03-01), pages 363 - 371, XP008169299, ISSN: 1933-7205, [retrieved on 20130724], DOI: 10.1177/1933719113497292
    EZZATI M ET AL: "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain", WOMEN'S HEALTH, FUTURE MEDICINE, UK, vol. 11, no. 1, 1 January 2015 (2015-01-01), pages 19 - 28, XP009188330, ISSN: 1745-5057, DOI: 10.2217/WHE.14.68
    IMANI R ET AL: "Petal study: safety, tolerability and effectiveness of elagolix, an oral GnRH antagonist for endometriosis", FERTILITY AND STERILITY, ELSEVIER SCIENCE INC, NEW YORK, NY, USA, vol. 92, no. 3, 1 September 2009 (2009-09-01), pages S111 - S112, XP026543194, ISSN: 0015-0282, [retrieved on 20090828], DOI: 10.1016/J.FERTNSTERT.2009.07.1100
    LINDA BJÖRKHEM-BERGMAN: "Quinine Compared to 4[beta]-Hydroxycholesterol and Midazolam as Markers for CYP3A Induction by Rifampicin", 25 August 2014 (2014-08-25), XP055324068, Retrieved from the Internet [retrieved on 20161129]
    NG J; SALEM A; CARTER D; WILLIAMS L A; KLEIN C E: "EFFECTS OF THE COADMINISTRATION OF SINGLE AND MULTIPLE DOSES OF RIFAMPIN ON THE PHARMACOKINETICS AND SAFETY OF ELAGOLIX IN HEALTHY PREMENOPAUSAL FEMALES, Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics (ASCPT); San Diego, CA, USA; March 08 -12, 2016", CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 99, no. Suppl. 1, PI-089, 1 February 2016 (2016-02-01), pages S54 - S55, XP009192577
    None

Cited By (0)

    Publication numberPublication dateAssigneeTitle